Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Ride the Tiger with CD -- Ignore unavailable to you. Want to Upgrade?

To: Cheeky Kid who wrote (159583)	5/20/2009 11:57:52 PM
From: Rocket Red	Read Replies (1) \| Respond to of 313686

Gap is miles ahead of them already In this model, human breast cancer of the type Estrogen Receptor negative, which as a group represents the 30 per cent of breast cancers which are not currently treatable by available drug therapies, were implanted into the bloodstream and provided with a seven-day period to allow tumours to form. The type of cancer cells implanted is known to be highly invasive to the lungs, within a three- to five-day period following implantation. Following this establishment period of seven days, the treatment regime began in the eight groups of five mice. In the group of five mice receiving PhG-alpha-1 at the dose of one milligram per kilogram of body weight, four of five (80 per cent) when euthanized at the end of the trial period were observed to be tumour-free on postmortem examination, with no effect on other organs. The remaining mouse had developed a single small, friable (easily broken down) tumour. _______________________________________________________________ saline and chemotherapy alone In the two control groups (saline and chemotherapy alone), nine of 10 (90 per cent) developed tumours, with only one surviving to the end of the trial and with ancillary organ damage to some degree. For all other treatment groups, 22 of 25 (88 per cent) developed tumours, and none survived to the end of the trial, again exhibiting ancillary organ damage.